208 related articles for article (PubMed ID: 31214486)
1. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
Chiricozzi A; De Simone C; Fossati B; Peris K
Psoriasis (Auckl); 2019; 9():29-35. PubMed ID: 31214486
[TBL] [Abstract][Full Text] [Related]
2. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of IL-17A and IL-17F in psoriatic disease.
Iznardo H; Puig L
Ther Adv Chronic Dis; 2021; 12():20406223211037846. PubMed ID: 34408825
[TBL] [Abstract][Full Text] [Related]
4. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S; Baeten D; Baker T; Griffiths M; Ionescu L; Lawson ADG; Maroof A; Oliver R; Popa S; Strimenopoulou F; Vajjah P; Watling MIL; Yeremenko N; Miossec P; Shaw S
Ann Rheum Dis; 2018 Apr; 77(4):523-532. PubMed ID: 29275332
[TBL] [Abstract][Full Text] [Related]
5. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
Ali Z; Matthews R; Al-Janabi A; Warren RB
Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies.
Sánchez-Rodríguez G; Puig L
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373452
[TBL] [Abstract][Full Text] [Related]
7. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
8. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
10. Bimekizumab for the treatment of psoriatic arthritis.
Tanaka Y; Shaw S
Expert Rev Clin Immunol; 2024 Feb; 20(2):155-168. PubMed ID: 37909894
[TBL] [Abstract][Full Text] [Related]
11. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy.
Kokolakis G; Ghoreschi K
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614836
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab: the new drug in the biologics armamentarium for psoriasis.
Freitas E; Torres T
Drugs Context; 2021; 10():. PubMed ID: 34178093
[TBL] [Abstract][Full Text] [Related]
14. Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.
Sakkas LI; Zafiriou E; Bogdanos DP
Front Pharmacol; 2019; 10():872. PubMed ID: 31447673
[TBL] [Abstract][Full Text] [Related]
15. An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.
Oliveira DG; Faria R; Torres T
Drug Des Devel Ther; 2021; 15():1045-1053. PubMed ID: 33727793
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab for Moderate-to-Severe Plaque Psoriasis.
Gotesman RD; Vender R
Skin Therapy Lett; 2021 May; 26(3):1-4. PubMed ID: 34077151
[TBL] [Abstract][Full Text] [Related]
17. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Burshtein J; Shah M; Zakria D; Lockshin B; Crowley J; Merola JF; Gordon K; Shahriari M; Korman NJ; Chovatiya R; Kalb R; Lebwohl M
Dermatol Ther (Heidelb); 2024 Feb; 14(2):323-339. PubMed ID: 38340237
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients.
Mahmoud AM
Curr Med Res Opin; 2023 Jul; 39(7):1031-1043. PubMed ID: 37345857
[TBL] [Abstract][Full Text] [Related]
20. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.
Ruggiero A; Potestio L; Camela E; Fabbrocini G; Megna M
Psoriasis (Auckl); 2022; 12():127-137. PubMed ID: 35707807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]